Drugs / HIV-1 Tat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01441193 | Sep 2011 → Feb 2014 | HIV infectious disease | Barbara Ensoli, MD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 Tat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01441193 ↗ |
| Known as | Tat | “Tat and delta-V2 Env proteins either in association or as single compounds were administered by a prime-boost regimen” NCT01441193 ↗ |
| Modality | Vaccine | “HIV-1 Tat vaccine 7.5 microg” NCT01441193 ↗ |
| Route | Intramuscular | “Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36” NCT01441193 ↗ |